Qizhen Shi, MD, PhD, and her laboratory have been awarded a number of grants that help them propel their lifesaving hemophilia A and hemophilia B research.
Recent grants include:
- R01 HL102035, “Platelet-derived FVIII gene therapy of hemophilia A,” Role: PI (2010-2024)
- R01 HL142791, “A phase I clinical trial testing feasibility of hematopoietic stem cell gene therapy using platelet FVIII to safely improve hemostasis for severe hemophilia A with inhibitory antibodies to FVIII,” Role: Co-I (2019-2024)
- Joan Cox Gill CCBD/MSI Clinical & Translational Pilot Award, "Evaluating T follicular helper cells in FVIII inhibitor development and ITI in patients with Hemophilia A", Role: PI (2021-2023)”.
MACC FUND, “FVIII immune responses in hemophilia A,” Role: PI